Success Metrics

Active Trials

1(20%)

Phase Distribution

Ph phase_2

80%

Ph phase_1

20%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution5 total trials

Phase 1Safety & dosage

1(20.0%)

Phase 2Efficacy & side effects

4(80.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(5)

Detailed Status

Not yet recruiting4

Recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

N/A

Most Advanced

Phase 2

Trials by Phase

Phase 11 (20.0%)

Phase 24 (80.0%)

Trials by Status

not_yet_recruiting480%

recruiting120%

Recent Activity

1 active trials

Showing 5 of 5

not_yet_recruitingphase_2

Neoadjuvant Iparomlimab/Tuvonralimab Plus CAPEOX Versus Iparomlimab/Tuvonralimab Plus CAPEOX and Propranolol for Locally Advanced pMMR Colon Cancer: A Prospective, Single-Center, Multi-Cohort Study

NCT07549906

not_yet_recruitingphase_2

Iparomlimab/Tuvonralimab + Standard Chemotherapy and Olaparib in Platinum-Sensitive Recurrent Ovarian Cancer

NCT07454018

recruitingphase_2

Iparomlimab/Tuvonralimab Injection Plus CCRT in LACC

NCT07232654

not_yet_recruitingphase_1

Surgery for Relapsed Ovarian Cancer in Precision

NCT06602063

not_yet_recruitingphase_2

Iparomlimab/Tuvonralimab Combined With Bevacizumab and CAPEOX as Conversion Therapy for Colorectal Cancer Liver Metastasis

NCT07007728

Clinical Trials (5)

Showing 5 of 5 trials

NCT07549906Phase 2

Neoadjuvant Iparomlimab/Tuvonralimab Plus CAPEOX Versus Iparomlimab/Tuvonralimab Plus CAPEOX and Propranolol for Locally Advanced pMMR Colon Cancer: A Prospective, Single-Center, Multi-Cohort Study

Not Yet Recruiting

NCT07454018Phase 2

Iparomlimab/Tuvonralimab + Standard Chemotherapy and Olaparib in Platinum-Sensitive Recurrent Ovarian Cancer

Not Yet Recruiting

NCT07232654Phase 2

Iparomlimab/Tuvonralimab Injection Plus CCRT in LACC

Recruiting

NCT06602063Phase 1

Surgery for Relapsed Ovarian Cancer in Precision

Not Yet Recruiting

NCT07007728Phase 2

Iparomlimab/Tuvonralimab Combined With Bevacizumab and CAPEOX as Conversion Therapy for Colorectal Cancer Liver Metastasis

Not Yet Recruiting

All 5 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 5